BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease

Posted: · Last updated:

BlueRock Therapeutics shared a news release on January 7, 2020 announcing the funding of a two-year trial using adult donor stem cells.

Parkinson Canada’s view:

This news is a “[s]ignificant development in North America as the US FDA approves it’s first trial to study the use of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease. The system uses adult donor cells as starting material and reprograms them into dopaminergic neurons that are transplanted into the Parkinson’s region of the brain. In New York, the two-year phase I clinical trial will enroll 10 patients and focus on examining the safety and tolerability of the transplant.”

Read the full article in context.

Leave a Reply

Your email address will not be published.